Anapharm Europe Announces Rebranding & Laboratory Expansion
We are pleased to announce that as part of our rebranding strategy, our brand name has now changed from Anapharm Europe to Anapharm Bioanalytics.
Our rebranding project is built on many improvements we have made to our services as well as on the international growth of our business. We have recently completed the expansion of our facilities in Barcelona increasing our lab space by 50%, acquired two additional ABSciex 6500 LC-MS/MS/UPLC platforms, upgraded software and hired additional staff in order to offer our clients increased capacity and improved study timelines for both small and large molecule bioanalysis.
The name change does not affect the legal personality of the existing entity (namely Anapharm Europe S.L.U.) which retains its rights and obligations in all existing legal relationships with third parties as well as the regulatory track record achieved to date including GLP and ANVISA certifications as well as FDA and EU-GCP inspection history.
What it means for our clients is that it is business as usual. We will continue to execute projects with the same, if not better, level of excellence and quality standards you have come to experience.
Our e-mail addresses will change but our phone numbers and headquarter’s address will remain the same. You can continue to connect with us online at our new website www.anapharmbioanalytics.com.
We take this opportunity to thank all our valued clients for their continued trust and look forward to delivering great value services that meet your expectations time after time.
Anapharm Bioanalytics’ successful FDA Inspection
Anapharm Bioanalytics is proud to announce that it has successfully undergone another US FDA inspection at its Barcelona based bioanalytical lab. The inspection, that took place in June 2019, had a focus on a total of 8 studies. This was the second unannounced FDA inspection at our facilities without any observations; no 483 form issued.READ MORE
Anapharm Bioanalytics has been acredited under the Gulf Health Council
Anapharm Bioanalytics is proud to announce that it has been recently added to the List of Bioequivalence Centres Approved by GCC, Gulf Cooperation Council (United Arab Emirates, Bahrain, Kingdom of Saudi Arabia, Sultanate of Oman, Qatar, Kuwait and Republic of Yemen).READ MORE
Anapharm Bioanalytics Brazilian ANVISA Certificate Renewal
Anapharm Bioanalytics is proud to announce that it has recently renewed its ANVISA (Brazil) certificate.
The renewed certification is valid until 11th June 2020.